The FDA route here is not just about pursuing the US market: the framework has already been agreed upon with the FDA, and it includes Fast Track and Orphan Drug status from both the FDA and EMA. While management turnover creates headlines of uncertainty, the path of the program itself has been stable and systematic.
14 Likes